Clinical trial
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria…
NCT00307021 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00307021 |
|---|---|
| Title | Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children |
| Official title | Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 |
| Enrollment | 180 |
| Start date | Apr 7, 2006 |
| Primary completion | Sep 15, 2006 |
| Completion | Aug 22, 2007 |
| First posted | Mar 27, 2006 |
| Last update posted | Apr 25, 2017 |
| Countries | Gabon |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: